Travessera de Gràcia, 11
The European Foundation for the Study of Chronic Liver Failure (EF-CLIF) is a non-profit organization, created with the aim of designing, promoting and supporting studies on the mechanism, prevention and treatment of liver cirrhosis and its complications; particularly, acute-on-chronic liver failure. In the origin of EF-CLIF lies the European Association for the Study of the Liver – Chronic Liver Failure (EASL-CLIF) consortium. An independent entity, the consortium, with 106 hospitals in 26 countries, is an important instrument for carrying out observational and therapeutic studies on large series of patients. Since its foundation (2009), the EASL-CLIF consortium’s most significant achievement has been in identifying, characterizing, establishing diagnostic criteria, designing new prognostic scoring, and understanding the mechanisms of a new syndrome (Acute-on-Chronic Liver Failure, ACLF), which constitutes the principal cause of death from cirrhosis. The recent creation of the Grifols Chair for Research and Education is a new drive in the international struggle against cirrhosis. It constitutes the second major activity of EF-CLIF. Its goal is to promote translational research in liver disease, especially cirrhosis, as well as disseminating knowledge regarding this disorder.
EF-CLIF is the coordinating institution of MICROB-PREDICT. It will deliver data from the CANONIC and PREDICT studies, samples from PREDICT, and participate in data analysis and validation. EF-CLIF will also be the sponsor of the clinical ALB-TRIAL and participate in dissemination efforts, deliver crucial information about ethics and health economics in the centres of PREDICT, and contribute to cost-efficiency of tools and treatments.